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ABSTRACT

This invention relates to a body fluids identification method
and kit. A parallel, multiplex reverse transcription-polymerase chain reaction (RT-PCR) assay for the definitive
identification of body fluids commonly encountered in
forensic casework analysis, namely blood, saliva, semen,
and vaginal secretions. The methodology is based on gene
expression profiling analysis in which the body fluid-specific genes are identified by detecting the presence of
appropriate messenger RNA species. Gene-specific primers
are labeled with fluorescent dyes, separated and subjected to
laser induced fluorescence for identification of body fluidspecific genes present in a sample stain.
9 Claims, 1 Drawing Sheet
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Primer Se9uences/d~es
5' - 6-FAM- agg atg get tgg cct tta at (Seq ID 1)
5'- act gee age ace ttc ate tt (Seq ID 2)
5' - TET- tgg ate cct gag gag ggc aga ag (Seq ID 3)
5'- tct tg! ccc ctg tgg tgg aca tag caa t {Seq ID 4)
5'- 6-FAM- ctt etg tag tct cat ctt g (Seq ID 5)
5' - tgg ttg tgg gta tag tgg ttg ttc (Seq ID 6)
5'- 6-FAM- gca aag aga cat cat ggg ta (Seq ID 7)
5' - gee agt caa ace tee ata ate {Seg ID 8}
5'- HEX- gee agg tac aga tgc tgt cge ag (Seq ID 9)
5' - tta gtg tct tct aca tct egg tct (Seq ID 10)
5 ' - 6-FAM- gtg agg age ctg age gaa egc (Seq ID 11)
5'- tta gtg cct tct gca tgt tet ctt c ~Se9 ID 12)
5'- 6-FAM- ttc ctg aaa tee tga gtg tt (Seq ID 13)
5' - taa cag gtg cct tga att tt (Seq ID 14)
5'- HEX- gga cca cat ttt ate agg aa (Seq ID 15)
5 ' - tag aga aac agg gca tag ga (Seq ID 16)

Figure 1

Size
247bp

177 bp
198 bp
134 bp
153 bp

294bp
213 bp
235 bp
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MESSENGER RNA PROFILING: BODY
FLUID IDENTIFICATION USING
MULTIPLEX REVERSE
TRANSCRIPTION-POLYMERASE CHAIN
REACTION (RT-PCR)

Molecular Marker for Spermatozoa in Semen Stains," International Journal of Legal Medicine Vol. 117 (2003) pages
175-179.
As more and more tissue-specific genes (mRNAs) are
identified for use in the positive identification of body fluids
and tissues of forensic importance, there is an increasing
need for a device or assay system that provides simultaneous
and semi-automatic analysis through a common assay format. The novel, multiplex, parallel assay system of the
present invention provides a common assay format and
offers many advantages over the conventional analysis procedures for body fluid identification.

This invention claims the benefit of priority from U.S.
Provisional Application Ser. No. 60/545,792 filed Feb. 19,
2004.
10

FIELD OF THE INVENTION
This invention relates to a ribonucleic acid (RNA) based
assay system and kit for body fluid identification, and in
particular to a novel, multiplex, parallel assay system based
on messenger RNA expressed in human tissue, and to a
method for using the same.
BACKGROUND AND PRIOR ART
Conventional methods of body fluid identification use a
variety of labor-intensive, technologically diverse techniques that are performed in a series, not parallel, manner
and are costly in terms of time and consumption of sample.
It used to be standard practice to perform biochemical,
serological, and immunological tests to identify the body
fluid(s) comprising a biological stain. Increasingly, however,
classical methods for body fluid identification have no
confirmatory technique for some frequently encountered
body fluids. For example, there is no definitive test for the
presence of saliva or vaginal secretions, and urine identification can be problematic. The need exists for a more
reliable, efficient assay system to supplant conventional
methods for body fluid identification.
Previous research in the development of a ribonucleic
acid (RNA) based assay system for the identification of body
fluids, included considerations for the use of protein and
messenger RNA (mRNA) since both are expressed in a
tissue-type specific manner. However, multiplex analysis of
complex protein mixtures, such as those present in body
fluid stains, requires further developments in the field of
proteomics. Whereas, with messenger RNA (mRNA), the
molecular intermediate between genetic DNA and expressed
protein is at present, supported by technologies for massively parallel analysis in the field of genomics.
As reported by B. Alberts, et al. Molecular Biology of the
Cell 3rd ed., Garland Publishing Inc., NY, 1994, a pattern of
gene expression is produced that is unique to each cell type
and is evinced by the presence as well as the relative
abundance of specific mRNAs. Each cell type, such as,
blood monocytes, lymphocytes, ejaculated spermatozoa,
epithelial cells lining the oral cavity or epidermal cells, has
a unique pattern of gene expression.
Specific gene expression patterns for saliva were reported
by J. Juusola and J. Ballantyne in February 2002 in a
presentation to the American Academy of Forensic Science
(AAFS) entitled, "The Development of an RNA Based
Assay System for Body Fluid Identification," and in Forensic Science International, Vol. 135 (2003) pages 85-96
("Messenger RNA Profiling: a Prototype Method to Supplant Conventional Methods for Body Fluid Identification").
Semen specific genes were reported by J. Juusola and J.
Ballantyne in "The Development of an RNA Based Assay
System for Body Fluid Identification," presented to AAFS,
February 2002. M. Bauer and D. Patzelt also identified
semen specific genes in an article, "Protamine mRNA as
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A primary objective of the present invention is to provide
facile identification of the tissue components present in a
body fluid stain.
A second objective of the present invention is to supplant
the battery of serological and biochemical tests currently
employed in the forensic serology laboratory.
A third objective of the present invention is to provide a
common assay format that provides greater specificity in the
identification of body fluids with improved timeliness.
A fourth objective of the present invention is to decrease
sample consumption during analysis of stains containing
body fluids.
A fifth objective of the present invention is to provide
simultaneous and semi-automated analysis through a common assay format.
A sixth objective of the present invention is to provide a
multiplex analysis of body fluids in an assay format that is
compatible with DNA extraction methodologies.
A seventh objective of the present invention is to provide
a kit that can be used to identify the source of at least four
body fluids from a human being found in a single stain or a
mixed stain.
A preferred method for preparing a multiplex, parallel
assay to identify the source of at least four body fluids from
a human being includes obtaining a sample stain consisting
of a body fluid from a human being, extracting total ribonucleic acid (RNA) from the sample stain, treating the total
RNA with an enzyme, initiating a reverse-transcriptase (RT)
reaction by treating total RNA with random decamers to
produce cDNA, amplifying the cDNA using gene-specific
primers, controlling the size of the amplified cDNA to allow
separation by electrophoresis, and identifying body fluidspecific genes present in the sample as either a single or a
mixed stain.
The total RNA is extracted with a denaturing solution,
such as, guanidine isothiocyanate-phenol:chloroform. Then,
the extracted total RNA is precipitated with an organic
solvent, such as, isopropanol. A preferred enzyme, such as,
deoxyribonuclease I (DNase I) is used to treat the extracted
total RNA.
The preferred multiplex assay is an octaplex composed of
eight body fluid-specific genes optimized for the detection of
body fluids from four specific body tissues. The fluids,
selected from four specific body tissues, are identified as,
blood, saliva, semen and vaginal secretions.
The gene-specific primers are labeled with fluorescent
dyes and are incorporated into a single multiplexed polymerase chain reaction (PCR) and the cDNA is amplified
prior to separation according to size. A preferred method of
separation is via capillary electrophoresis. The separated
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PCR product is then subjected to laser induced fluorescence
for identification of body fluid-specific genes present in a
sample stain.
Eight body fluid-specific genes are used in a multiplex,
parallel assay and the eight body fluid-specific genes are
selected from the group consisting of: beta-spectrin (SPTB),
porphobilinogen deaminase (PBGD), the erythoid-specific
variant known as variant 2, statherin (STATH), bistatin 3
(HTN3), protamine 1 (PRMl), protamine 2 (PRM2), mucin
4 (MUC4) and human beta-defensin 1 (HBDl).
The messenger RNA genes for human blood are identified
as beta-spectrin (SPTB) and porphobilinogen deaminase
(PBGD). The messenger RNA genes for vaginal secretions
are identified as mucin 4 (MUC4) and human beta-defensin
1 (HBDl).
A kit is provided for use in preparing a multiplex, parallel
assay to identify the source of at least four body fluids from
a human being, comprising PCR primers pre-selected from
4 or more of the group consisting of 8 body fluid-specific
gene primers constructed from SPTB, PBGD, STATH,
HTN3, PRMl, PRM2, MUC4, and HBD-1 genes. In the
kits, PCR primers are tagged with fluorescent dyes. It is
possible to redesign primers for one or more of the body
fluid-specific genes and it is understood that the redesigned
primers are within the scope of the present invention.
Further objects and advantages of this invention will be
apparent from the following detailed description and
example of a presently preferred embodiment.

a body fluid identification system or method. A number of
design factors and assay quality controls ensure that the
tissue-specific RT-PCR assays disclosed herein detect
mRNA and not genomic DNA.
The two body fluid-specific genes for each of four body
fluids that are the subject of the present invention, are
identified in Table I below.

BRIEF DESCRIPTION OF THE DRAWING

TABLE I
10
BODYFLUIDSPECIFIC GENE:
beta-spectrin
(SPTB)
porphobilinogen
15
dearninase
(PBGD)
statherin (STATH)
histatin 3 (HTN3)
protarnine 1

20

Before explaining the disclosed embodiments of the
present invention in detail it is to be understood that the
invention is not limited in its application to the details of the
particular arrangements shown since the invention is capable
of other embodiments. Also, the terminology used herein is
for the purpose of description and not of limitation.
The invention provides a multiplex, parallel assay to
identify the tissue source for at least four body fluids from
a human being. The first step in the development of the
invention is the identification of tissue-specific genes that
are expressed in only one tissue. For example, each tissue
type is comprised of cells that have a unique transcriptome,
or gene expression profile, also known as the messenger
ribonucleic acid (mRNA). The collection of genes that are
expressed within the constellation of differentiated cells that
make up a body fluid is called the multicellular transcriptome. These genes comprise ubiquitously expressed housekeeping genes, which are responsible for cell maintenance
functions, and genes that are specifically expressed in certain
tissues only.
The mRNA molecules are present in different quantities
depending on the particular species of mRNA and the cell
type, and can be classified as abundant, moderately abundant
and rare. Although the present invention is dependent on the
identification of tissue-specific mRNA molecules, it is not to
be considered a limitation of the invention. As previously
discussed, tissue-specific genes are still in the process of
being identified.
In addition to identifying two body fluid-specific genes
for each of four body fluids, the present invention provides

BLOOD
BLOOD

SALNA
SALNA
SEMEN

~~=:ne 2

SEMEN

(PRM2)
mucin 4
(MUC4)
human betadefensin 1 (HBDl)

VAGINAL
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SECRETIONS
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FIG. 1 shows the sequences of the PCR primers for the
various body fluid specific genes used in the assay.
DESCRIPTION OF THE PREFERRED
EMBODIMENTS

BODY FLUIDS

35

Fluorescent dye-labeled primers for the eight genes identified above, are incorporated into a single, multiplexed
polymerase chain reaction (PCR). Following amplification,
the PCR product is separated according to size with capillary
electrophoresis and detected using laser induced fluorescence. The resulting profile, or collection of specific peaks
on the electropherogram that represent the body fluidspecific genes, identify the body fluids that are present in the
sample as a single or mixed stain. For this invention, the
body fluids include, but are not limited to, blood, saliva,
semen or vaginal secretions.
The following example provides further explanation of
the present invention.
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A physiological stain is prepared by collecting human
blood via venipuncture; collecting 50 microliter (µl) aliquots
placed onto cotton gauze and dried at room temperature.
Freshly ejaculated semen is collected in plastic cups, and
allowed to dry onto cotton swabs at room temperature.
Buccal scrapings and saliva samples were obtained on
cotton swabs, and dried at room temperature. Vaginal secretions, such as menstrual blood, are also obtained and dried
at room temperature. For RNA or DNA isolation a 50
microliter (µl) blood or saliva stain, or a single semen,
vaginal secretion, or menses blood stained cotton swab is
used.
For RNA isolation, total RNA is extracted from blood,
saliva, vaginal and semen stains with a denaturing solution,
such as, guanidine isothiocyanate-phenol:chloroform and
precipitated with isopropanol. Next, the extracted total RNA
is treated with an enzyme, deoxyribonuclease I (DNase I),
and then reverse-transcribed using random decamers as the
first strand primer, producing complementary DNA (cDNA).
Finally, the cDNA is amplified using gene-specific primers.
The RT-PCR amplimer sizes are carefully chosen to span the
range of approximately 100 base pairs to approximately 300
base pairs, wherein base pairs is the size of amplified
product, to allow facile separation by standard electrophoresis on agarose gels or by capillary electrophoresis.

US 7,270,983 Bl
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The primers are custom synthesized commercially. Primers for PBGD, PRMl, and PRM2 are described by A. N.
Gubin and J. L. Miller, in "Human erythroid porphobilinogen deaminase exists in 2 splice variants." Blood, 97 (2001)
pages 815-817, and K. Steger, K. Pauls, T. Klonisch, F. E.
Franke and M. Bergmann, "Expression of Protamine-1
and -2 mRNA during human spermiogenesis." Mal. Hum.
Reprod. 6 (2000) 219-225. The primer sequences (and
expected product sizes) are shown in FIG. 1. The assay of
the present invention, includes, but is not limited to, the
primer sequences listed herein. A person skilled in the art
will readily recognize that it is possible to redesign primers
for one or more of the genes and it is understood that the
redesigned primers are within the scope of the present
invention.
The multiplex PCR reaction mixture contains buffer (10
mM Tris-HCI, pH 8.3, 50 mM KC!), 3.5 mM MgCl 2 , 0.125
mM each dNTP, 5.48 µM PCRprimers (see above), and 1.25
units of DNA Polymerase. The PCR primer pairs are added
in the following concentrations: SPTB, 0.8 µM; PBGD, 0.24
µM; STATH, 0.4 µM; HTN3, 0.4 µM; PRMl, 0.04 µM;
PRM2, 0.4 µM; HBD-1, 1.6 µM; MUC4, 1.6 µM. The
standard PCR conditions used for the multiplex consists of
a denaturing step (95° C., 11 min) followed by 35 cycles
(94° C., 20 sec; 55° C., 30 sec; 72° C., 40 sec) and a final
extension step (72° C., 5 min) using a thermocycler instrument.
Based on the above extraction and separation techniques,
a multiplex RT-PCR assay is developed for the definitive
identification of all of the body fluids commonly encoun-

tered in forensic casework analysis, namely blood, saliva,
semen and vaginal secretions. The octaplex is composed of
eight body fluid-specific genes and has been optimized for
the detection of blood, saliva, semen, and vaginal secretions
as single or mixed stains. The methodology is based on gene
expression profiling analysis in which the body fluid-specific genes are identified by detecting the presence of
appropriate mRNA species. The gene-specific primers are
labeled with fluorescent dyes (such as Tet or Hex or Fam as
indicated in FIG. 1) incorporated into a single multiplexed
polymerase chain reaction (PCR). The cDNA is amplified
using PCR, and the PCR product is separated according to
size using a capillary electrohoresis instrument, and detected
using laser induced fluorescence. The resulting profile identifies those body fluids present in a single or mixed stain.
Advantages of the mRNA-based approach, compared to
conventional biochemical analysis include, but are not limited to, greater specificity, simultaneous and semi-automated
analysis through a common assay format, improved timeliness, decreased sample consumption and compatibility with
DNA extraction methodologies.
While the invention has been described, disclosed, illustrated and shown in various terms of certain embodiments or
modifications which it has presumed in practice, the scope
of the invention is not intended to be, nor should it be
deemed to be, limited thereby and such other modifications
or embodiments as may be suggested by the teachings herein
are particularly reserved especially as they fall within the
breadth and scope of the claims here appended.
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 16
<210>
<211>
<212>
<213>

SEQ ID NO 1
LENGTH: 20
TYPE: DNA
ORGANISM: Homo sapiens

<400> SEQUENCE: 1
aggatggctt ggcctttaat

<210>
<211>
<212>
<213>

20

SEQ ID NO 2
LENGTH: 20
TYPE: DNA
ORGANISM: Homo sapiens

<400> SEQUENCE: 2
actgccagca ccttcatctt

<210>
<211>
<212>
<213>

20

SEQ ID NO 3
LENGTH: 23
TYPE: DNA
ORGANISM: Homo sapiens

<400> SEQUENCE: 3
tggatccctg aggagggcag aag

<210>
<211>
<212>
<213>

SEQ ID NO 4
LENGTH: 28
TYPE: DNA
ORGANISM: Homo sapiens

23

US 7,270,983 Bl
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-continued

<400> SEQUENCE: 4
tcttgtcccc tgtggtggac atagcaat

<210>
<211>
<212>
<213>

28

SEQ ID NO 5
LENGTH: 19
TYPE: DNA
ORGANISM: Homo sapiens

<400> SEQUENCE: 5
cttctgtagt ctcatcttg

<210>
<211>
<212>
<213>

19

SEQ ID NO 6
LENGTH: 24
TYPE: DNA
ORGANISM: Homo sapiens

<400> SEQUENCE:
tggttgtggg tatagtggtt gttc

<210>
<211>
<212>
<213>

24

SEQ ID NO 7
LENGTH: 20
TYPE: DNA
ORGANISM: Homo sapiens

<400> SEQUENCE:
gcaaagagac atcatgggta

<210>
<211>
<212>
<213>

20

SEQ ID NO 8
LENGTH: 21
TYPE: DNA
ORGANISM: Homo sapiens

<400> SEQUENCE:
gccagtcaaa cctccataat c

<210>
<211>
<212>
<213>

21

SEQ ID NO 9
LENGTH: 23
TYPE: DNA
ORGANISM: Homo sapiens

<400> SEQUENCE:
gccaggtaca gatgctgtcg cag

<210>
<211>
<212>
<213>

23

SEQ ID NO 10
LENGTH: 24
TYPE: DNA
ORGANISM: Homo sapien

<400> SEQUENCE: 10
ttagtgtctt ctacatctcg gt ct

<210>
<211>
<212>
<213>

24

SEQ ID NO 11
LENGTH: 21
TYPE: DNA
ORGANISM: Homo sapien

<400> SEQUENCE: 11
gtgaggagcc tgagcgaacg c

<210>
<211>
<212>
<213>

SEQ ID NO 12
LENGTH: 25
TYPE: DNA
ORGANISM: Homo sapien

21
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10
-continued

<400> SEQUENCE: 12
ttagtgcctt ctgcatgttc tcttc

<210>
<211>
<212>
<213>

25

SEQ ID NO 13
LENGTH: 20
TYPE: DNA
ORGANISM: Homo sapien

<400> SEQUENCE: 13
ttcctgaaat cctgagtgtt

<210>
<211>
<212>
<213>

20

SEQ ID NO 14
LENGTH: 20
TYPE: DNA
ORGANISM: Homo sapien

<400> SEQUENCE: 14
20

taacaggtgc cttgaatttt

<210>
<211>
<212>
<213>

SEQ ID NO 15
LENGTH: 20
TYPE: DNA
ORGANISM: Homo sapien

<400> SEQUENCE: 15
20

ggaccacatt ttatcaggaa

<210>
<211>
<212>
<213>

SEQ ID NO 16
LENGTH: 20
TYPE: DNA
ORGANISM: Homo sapien

<400> SEQUENCE: 16
20

tagagaaaca gggcatagga
40

We claim:
1. A method for preparing a multiplex, parallel assay to
identify the source of body fluids from a human being
selected from the group consisting of one or more of blood,
saliva, semen and vaginal secretions, comprising the steps
of:
a) obtaining a sample stain consisting of a single body
fluid or multiple fluids from a human being;
b) extracting total ribonucleic acid (RNA) from the
sample stain;
c) treating the total RNA with an enzyme;
d) initiating a reverse-transcriptase (RT) reaction by treating total RNA with random decamers to produce
cDNA;
e) amplifying said cDNA using gene-specific primer pairs
for each of the genes SPTB, PBGD, STATH, HTN3,
PRMl, PRM2, MUC4, and HBD-1, wherein each gene
is related to a specific human body fluid; SPTB and
PBGD being genes specific for blood; STATH and
HTN3 being genes specific for saliva; PRMl and
PRM2 being genes specific for semen; and HBD-1 and
MUC4 being genes specific for vaginal secretions;
f) controlling the size of the amplified cDNA to allow
separation by electrophoresis; and
g) identifying the body fluid-specific genes present in the
sample, wherein the presence of one or more of said

body fluid specific genes identifies the source of the
body fluid(s) in the sample.
45

50

55

60

2. The method of claim 1, wherein the total RNA is
extracted with a denaturing solution.
3. The method of claim 2, wherein the solution is guanidine isothiocyanate-phenol:chloroform.
4. The method of claim 3, wherein the extracted total
RNA is precipitated with an organic solvent.
5. The method or claim 4, wherein the organic solvent is
isopropanol.
6. The method of claim 1, wherein the enzyme used to
treat the extracted total RNA is deoxyribonuclease I (DNase
I).
7. The method of claim 1, wherein the gene-specific
primers in step c) are labeled with fluorescent dyes.
8. The method of claim 1 wherein the gene specific
primers are selected from the group consisting of Sequence
IDs 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16.
9. The method of claim 7, wherein the gene specific
primers are selected from the group consisting of Sequence
IDs 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16.
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